NICE recommends GSK's Zejula for routine NHS commissioning
UK pharma major GlaxoSmithKline (LSE: GSK) has today welcomed a decision by UK health technology assessor the National Institute for Health and Care Excellence (NICE) to issue a Final Appraisal Determination (FAD) recommending the use of Zejula (niraparib) on the National Health Service (NHS).
Niraparib is recommended for use as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer, that has responded to the most recent course of platinum-based chemotherapy in adults. The drug was first cleared by the NICE to be available via the Cancer Drugs Fund (CDF) in January 2021.
It is recommended only if they have a germline BRCA mutation and have had two courses of platinum-based chemotherapy or they do not have a germline BRCA mutation and have had two or more courses of platinum-based chemotherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze